Wells Fargo analyst Stephen Baxter raised the firm’s price target on Oscar Health to $24 from $20 and keeps an Overweight rating on the shares. The firm is also increasing its 2024 adjusted EBITDA estimate by $75M following an encouraging start to 2024. Wells remains constructive ahead of I-Day, where Oscar Health is to provide financial targets and a strategic update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR: